Brief: Renovorx Reports Full Year 2022 Financial Results And Achievement Of Important Phase III Clinical Study Milestone
02/03/2023 14:16
March 2 (Reuters) - RenovoRx Inc RNXT.O :
* RENOVORX REPORTS FULL YEAR 2022 FINANCIAL RESULTS AND
ACHIEVEMENT OF IMPORTANT PHASE III CLINICAL STUDY MILESTONE
* RENOVORX INC FY LOSS PER SHARE $1.09
* ESTIMATE THAT CURRENT CAPITAL RESOURCES WILL BE SUFFICIENT
TO
FUND OP EXPENSES & CAP EX REQUIREMENTS INTO Q3 2023
Source text for Eikon: ID:nBw90WPtCa
Further company coverage: RNXT.O
Recent news on RenovoRx
See all newsBrief: RenovoRx Gets FDA Orphan Drug Designation For Oxaliplatin To Treat Pancreatic Cancer
RenovoRx Q1 revenue rises as number of active cancer centers increase
RenovoRx 2025 net loss widens on higher operating expenses
Brief: RenovoRx FY Net Income USD -11.168 Million
U.S. STOCKS ON THE MOVE-Vertex Pharma, U.S. Energy Corp, SoFi Technologies